Jonathon Holt Ph.D., DABT, has extensive experience leading product development programs. He has led more than 12 programs from research through clinical development. Dr. Holt’s core expertise is in nonclinical strategy and execution with the ability to develop and pursue stage-appropriate regulatory strategy at the nonclinical, CMC, and formulation level. He also has extensive experience with drug delivery devices, NCE combinations, drug-drug-device combination and the 505(b)(2) path. Prior to working at Nuventra, Dr. Holt worked at Adamas Pharmaceuticals, the International Partnership for Microbicides Mount Cook Pharma, Neuro 3D, and Ardent Pharmaceuticals. His therapeutic area experience includes CNS, Viral Disease, Neurological Disease, and Women’s Health.